Surfactin was thought to prevent T2DM by, first, reversing pancreatic dysfunctions through reducing oxidative stress, ERS and inflammatory responses, and second, improving insulin resistance by regulating the PI3K/AKT signaling pathway. The gene discussed is AKT1; the disease is Insulin resistance.